TNON on Nasdaq
Tenon Medical, Inc.
American surgical and medical instruments and apparatus company.
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with INTELLIGENT BIO SOLUTIONS INC., IceCure Medical or Nuo Therapeutics, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
59.8%Gross margin3
-324.3%Operating margin3
-318.4%Net margin3
20.4%Revenue growth, 20253
-249.1%Return on equity3
-$11.0MFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue40¢$1.6M
- Research and development54¢$2.1M
- Other costs5¢$209.0K
Out of $3.9M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $3.9M | $3.3M |
| Cost of sales | $1.6M | $1.6M |
| Gross Profit | $2.4M | $1.7M |
| General and administrative | $7.0M | $7.8M |
| Sales and marketing | $6.0M | $5.1M |
| Research and development | $2.1M | $2.6M |
| Total Operating Expenses | $15.2M | $15.5M |
| Loss from Operations | -$12.8M | -$13.8M |
| Gain on investments | $236.0K | $183.0K |
| Interest expense | -$34.0K | |
| Other expense, net | -$56.0K | |
| Total Other Income, net | $236.0K | $93.0K |
| Net Loss | -$12.6M | -$13.7M |
| Basic (in Dollars per share) | -$1.70 | -$11.26 |
| Diluted (in Dollars per share) | -$1.70 | -$11.26 |
| Basic (in Shares) | 7.4K shares | 1.2K shares |
| Diluted (in Shares) | 7.4K shares | 1.2K shares |
| Foreign currency translation adjustment | $46.0K | |
| Total Comprehensive Loss | -$12.6M | -$13.6M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 5 quarters (quarterly), latest first.3
| Period ending | 2026-02-28 | 2025-12-31 | 2025-10-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $3.8M | $6.5M | |||
| Accounts receivable, net | $1.7M | $863.0K | |||
| Inventory | $1.1M | $606.0K | |||
| Prepaid expenses and other current assets | $260.0K | $206.0K | |||
| Total current assets | $6.8M | $8.2M | |||
| Property and equipment, net | $918.0K | $752.0K | |||
| Deposits | $51.0K | $51.0K | |||
| Operating lease right-of-use asset | $131.0K | $399.0K | |||
| Deferred offering costs | $431.0K | ||||
| Intangible assets, net (Notes 3 and 6) | $485.0K | ||||
| Goodwill (Note 3) | $2.4M | ||||
| TOTAL ASSETS | $10.8M | $9.8M | |||
| Accounts payable | $845.0K | $369.0K | |||
| Accrued expenses | $1.6M | $910.0K | |||
| Current portion of accrued commissions | $590.0K | $303.0K | |||
| Current portion of operating lease liability | $141.0K | $287.0K | |||
| Total current liabilities | $3.2M | $1.9M | |||
| Accrued commissions, net of current portion | $1.5M | $1.9M | |||
| Operating lease liability, net of current portion | $141.0K | ||||
| Contingent consideration (Note 3) | $993.0K | ||||
| Total liabilities | $5.7M | $3.9M | |||
| Common stock, $0.001 par value; 130,000,000 shares authorized at December 31, 2025 and 2024; 10,851,273 and 3,138,804 shares issued and outstanding at December 31, 2025 and 2024, respectively | $11.0K | $3.0K | |||
| Additional paid-in capital | $83.3M | $71.0M | |||
| Accumulated deficit | -$81.3M | -$68.7M | |||
| Total stockholders equity | $5.0M | $6.0M | $778.0K | ||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $10.8M | $9.8M | |||
| Common stock, per share | $1.00 | $0.00 | $0.00 | $0.00 | |
| Common stock, shares authorized | 130.0M shares | 130.0M shares | |||
| Common stock, shares outstanding | 10.9M shares | 3.1M shares | |||
| Common stock, shares issued | 10.9M shares | 3.1M shares |
| Period ending | 2026-02-28 | 2025-12-31 | 2025-10-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $3.8M | $6.5M | |||
| Accounts receivable, net | $1.7M | $863.0K | |||
| Inventory | $1.1M | $606.0K | |||
| Prepaid expenses and other current assets | $260.0K | $206.0K | |||
| Total current assets | $6.8M | $8.2M | |||
| Property and equipment, net | $918.0K | $752.0K | |||
| Deposits | $51.0K | $51.0K | |||
| Operating lease right-of-use asset | $131.0K | $399.0K | |||
| Deferred offering costs | $431.0K | ||||
| Intangible assets, net (Notes 3 and 6) | $485.0K | ||||
| Goodwill (Note 3) | $2.4M | ||||
| TOTAL ASSETS | $10.8M | $9.8M | |||
| Accounts payable | $845.0K | $369.0K | |||
| Accrued expenses | $1.6M | $910.0K | |||
| Current portion of accrued commissions | $590.0K | $303.0K | |||
| Current portion of operating lease liability | $141.0K | $287.0K | |||
| Total current liabilities | $3.2M | $1.9M | |||
| Accrued commissions, net of current portion | $1.5M | $1.9M | |||
| Operating lease liability, net of current portion | $141.0K | ||||
| Contingent consideration (Note 3) | $993.0K | ||||
| Total liabilities | $5.7M | $3.9M | |||
| Common stock, $0.001 par value; 130,000,000 shares authorized at December 31, 2025 and 2024; 10,851,273 and 3,138,804 shares issued and outstanding at December 31, 2025 and 2024, respectively | $11.0K | $3.0K | |||
| Additional paid-in capital | $83.3M | $71.0M | |||
| Accumulated deficit | -$81.3M | -$68.7M | |||
| Total stockholders equity | $5.0M | $6.0M | $778.0K | ||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $10.8M | $9.8M | |||
| Common stock, per share | $1.00 | $0.00 | $0.00 | $0.00 | |
| Common stock, shares authorized | 130.0M shares | 130.0M shares | |||
| Common stock, shares outstanding | 10.9M shares | 3.1M shares | |||
| Common stock, shares issued | 10.9M shares | 3.1M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$12.6M | -$13.7M |
| Stock-based compensation expense | $1.7M | $3.8M |
| Depreciation and amortization | $262.0K | $408.0K |
| Provision for losses on accounts receivable | $16.0K | $41.0K |
| Amortization of operating right-of-use asset | $268.0K | $247.0K |
| Accounts receivable | -$851.0K | -$386.0K |
| Inventory | -$387.0K | -$52.0K |
| Prepaid expenses and other assets | -$35.0K | $183.0K |
| Accounts payable | $486.0K | -$64.0K |
| Accrued expenses | $648.0K | -$171.0K |
| Operating lease liability | -$287.0K | -$256.0K |
| Net cash used in operating activities | -$10.7M | -$9.9M |
| Purchase of assets from SiVantage, Inc. | -$750.0K | |
| Purchases of property and equipment | -$273.0K | -$186.0K |
| Net cash used in investing activities | -$1.0M | -$186.0K |
| Gross proceeds from issuance of common stock, prefunded warrants, and warrants | $4.0M | $4.5M |
| Gross proceeds from exercise of warrants under inducement agreement | $3.1M | $4.6M |
| Gross proceeds from issuance of common stock and warrants | $2.9M | |
| Gross proceeds from issuance of Series A convertible preferred stock | $2.6M | |
| Gross proceeds from issuance of Series B convertible preferred stock | $550.0K | |
| Gross proceeds from issuance of common stock | $2.1M | |
| Gross proceeds from exercise of warrants | $812.0K | |
| Offering costs | -$928.0K | -$1.1M |
| Net cash provided by financing activities | $9.0M | $14.1M |
| Effect of foreign currency translation on cash flow | $46.0K | |
| Net (Decrease) Increase in Cash and Cash Equivalents | -$2.8M | $4.1M |
| Warrant modification costs | $5.1M | $992.0K |
| Preferred stock issued upon conversion of debt and accrued interest | $1.2M | |
| Reclassification of deferred offering costs to additional paid-in capital | $421.0K | $367.0K |
| Common stock issued upon conversion of Series A preferred stock | $678.0K | |
| Common stock issued for purchase of assets from SiVantage, Inc. | $1.4M | |
| Contingent consideration for purchase of assets from SiVantage, Inc. | $1.0M |
No quarter-by-quarter statement was filed.
Leadership
Who has led Tenon Medical, Inc., and when. Pick a name to see everywhere that person has worked.
Chief financial officer
2025
- Chief financial officerDick Steven M. Van Apr 26, 2022 to Feb 13, 20249
Board members and other officers (10)
- Chief Innovation OfficerWyatt D. Geist Aug 11, 2025 to now10
- Chief Commercial OfficerNathaniel A. Grawey Aug 13, 2025 to now11
- Chief Technology OfficerRichard Ginn Apr 26, 2022 to now12
- Board memberKristine M. Jacques Mar 29, 2024 to now13
- Board memberFrank M. Fischer Apr 26, 2022 to May 24, 202314
- Board memberIvan Howard Apr 26, 2022 to now15
- Board memberRichard Ginn Apr 26, 2022 to now12
- Board memberRichard M. Ferrari Apr 26, 2022 to now16
- Board memberRobert K. Weigle Apr 26, 2022 to now17
- Board memberStephen Hochschuler Apr 26, 2022 to now18
Filings
294 filings to the SEC since October 2021: 4 annual reports, 14 quarterly reports, 60 major events, 75 insider forms, 10 large holders, 11 private raises, 120 other. The latest 20:
- Oct 9, 2026EFFECT EDGAR
- Oct 9, 2026424B3 PROSPECTUS EDGAR
- Oct 9, 20263 EDGAR
- Oct 5, 2026S-3 REGISTRATION STATEMENT EDGAR
- Sep 21, 2026D EDGAR
- Sep 16, 20268-K CURRENT REPORT EDGAR
- Sep 11, 20264 PRIMARY DOCUMENT EDGAR
- Sep 10, 20264 EDGAR
- Sep 9, 20268-K CURRENT REPORT EDGAR
- Sep 8, 20264 PRIMARY DOCUMENT EDGAR
- Sep 8, 2026424B3 PROSPECTUS EDGAR
- Sep 4, 2026EFFECT EDGAR
- Sep 4, 2026D EDGAR
- Sep 3, 20264 PRIMARY DOCUMENT EDGAR
- Sep 2, 2026S-3/A AMENDMENT NO. 2 TO FORM S-3 EDGAR
- Sep 1, 20264 PRIMARY DOCUMENT EDGAR
- Aug 31, 20264 PRIMARY DOCUMENT EDGAR
- Aug 31, 20263 PRIMARY DOCUMENT EDGAR
- Aug 31, 20268-K CURRENT REPORT EDGAR
- Aug 26, 20268-K/A AMENDMENT NO. 1 TO FORM 8-K EDGAR
The 294 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 10 such filings since October 2021:
- Aug 14, 2026SCHEDULE 13G
- Jul 6, 2026SCHEDULE 13G
- Aug 8, 2025SCHEDULE 13D
- Oct 4, 2024SC 13G
- Aug 8, 2024SC 13G
- Aug 8, 2024SC 13G/A
- Apr 16, 2024SC 13G
- Feb 14, 2024SC 13G/A
- Sep 13, 2023SC 13G/A
- May 17, 2022SC 13G
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Money raised
Private offerings the company reported to the SEC on Form D.
- Sep 11, 2026Raised $4.3 million in a private offering of securities Form D: 1 investor so far Form D
- Aug 27, 2026Raised $3 million in a private offering of equity Form D: 1 investor so far Form D
- Mar 11, 2026Raised $4.3 million in a private offering of debt Form D: 6 investors so far Form D
- Nov 10, 2025Raised $2.9 million in a private offering of equity Form D: 29 investors so far Form D
- Mar 25, 2025Raised $1.5 million in a private offering of securities Form D: 1 investor so far Form D
- Mar 25, 2025Raised $2.5 million in a private offering of securities Form D: 1 investor so far Form D
- Mar 12, 2025Raised $4.6 million in a private offering of securities Form D: 1 investor so far Form D
- Feb 20, 2024Raised $2.6 million in a private offering of equity Form D: $6 million offered in all Form D
- Nov 21, 2023Raised $1.2 million in a private offering of debt Form D: 2 investors so far Form D
- Jul 24, 2023Raised $286,835 in a private offering of equity Form D: 1 investor so far Form D
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13SEC EDGARKristine M. Jacques, Board member
- 14SEC EDGARFrank M. Fischer, Board member
- 15SEC EDGARIvan Howard, Board member
- 16SEC EDGARRichard M. Ferrari, Board member
- 17SEC EDGARRobert K. Weigle, Board member
- 18SEC EDGARStephen Hochschuler, Board member